Anthrax Vaccine Market

Anthrax is a severe infectious disease caused by bacillus anthracis. Signs and symptoms include vomiting, nausea, abdominal pain, headache, and loss of appetite, fever, severe bloody diarrhoea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors for anthrax include injection of illegal drugs, handling animal skins, and working in veterinary medicine, especially dealing with livestock. Global anthrax market is driven by growing threat of communicable diseases such as anthrax across the globe. Moreover cost-effectiveness of immunizations, new funding opportunities from government, donors, research foundations, advances in research and manufacturing technologies expected to drive market revenue growth of anthrax vaccine over a forecast period. In addition, availability of large target population in emerging markets driving the growth of the anthrax vaccines market. However, lack of awareness, the high cost of the vaccine in under developed economies, lack of availability and affordability, stringent regulations are the factors which are restraining the growth of the anthrax vaccine market.

Global anthrax vaccine market is segmented based on the type of vaccine, end user and geographical regions.

On the basis of type of vaccine, anthrax vaccine market is segmented as
Live Vaccines
Cell free PA Vaccines

On basis of end user, anthrax vaccine market is segmented as
Vaccination Centres

The growing efforts and of interest market players in expanding the product portfolio related to anthrax prevention are expected to to impel the market growth over the forecast period. Growing government funding in the United States to generate and store sufficient vaccines against anthrax through various programs, such as Joint Program Executive Office for Chemical and Biological Defense, Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation and is creating market opportunities for the market players. One of the U.S. FDA approved products against anthrax is BioThrax, manufactured by Emergent BioDefense Operations Lansing LLC, for active immunization against anthrax.

Geographically, Global anthrax vaccine is segmented into five key regions Viz. North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa. North America market expected to present better growth opportunities for market players owing to government initiatives to curb anthrax. The presence of various ongoing programs under the organizations such as BARDA, HHSCDC, NIAID, ASPR, and the FDA is one of the key contributing factors for the revenue generation in North America region. Asia Pacific is expected to witness a significant demand on account of surging investments in the R&D sector. The extensive vaccine manufacturing facilities across Japan coupled with the presence of sophisticated healthcare infrastructure in the country is contributing to its strong market position.

Some of the players in the anthrax vaccines market are Emergent BioSolutions (US), Elusys Therapeutics (US), Porton Biopharma Limited (UK), and Panacea Biotec (India) to name a few.

In 2015, Emergent BioDefense Operations Lansing LLC received U.S. FDA approval for its BioThrax, a vaccine for Anthrax.

Report Outline:
The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario